(334 days)
Indicated for prescription use to acquire, record, transmit, and data for electroencephalograph studies of patients of all ages.
The BrainMaster™ Discovery 24 are two-channel, four- channel, and 24-channel electrophysiological acquisition and biofeedback devices. The 24-channel (Discovery 24) digital EEG devices use industry-accepted Windowsbased PC as the control and display console. The devices consist of the following: BrainMaster™ Discovery 24 Hardware Module, BrainMaster™ software - BrainMaster™ BrainAvatar Acquisition software, Electrocap, which is sold separately. The system also includes a full set of DIN-compliant touch-proof sockets, either on the main housing, or in an accessory cable, that allows the use of "free sensors" without a cap. These products are designed for use with a standard IBM PC/AT compatible computers (Windows 7 and later) and associated peripheral equipment such as keyboard, mouse, and monitor(s). When assembled with a computer, the BrainMaster™ Discovery 24 system will acquire EEG and display and save it to disc.
The provided text is a 510(k) summary for the BrainMaster Discovery 24, an electroencephalograph. It details the device's technical specifications and compares it to a predicate device, but it does not contain information about acceptance criteria or a study proving that the device meets those criteria from an AI performance perspective.
The document primarily focuses on:
- Regulatory clearance: Demonstrating substantial equivalence to a predicate device (Cleveland Clinic Vanguard System).
- Device description: Outlining the hardware and software components of the Discovery 24.
- Technical comparison: A table comparing specifications between the Discovery 24 and the predicate device.
- Non-clinical testing: Adherence to IEC standards for electrical medical equipment and software validation.
- Absence of clinical tests: Explicitly stating "Not applicable."
Therefore, I cannot extract the requested information regarding acceptance criteria and a study proving the device meets those criteria as if it were an AI performance study. The device described is a medical instrument for acquiring EEG data, not an AI-driven diagnostic or analytical tool with performance metrics like accuracy, sensitivity, or specificity against established ground truth.
If you are looking for information regarding acceptance criteria related to the technical performance of the EEG device itself (e.g., signal quality, noise levels, sampling rates), these are implicitly covered by the "Non-Clinical Tests Performed" section which references IEC standards and software validation. However, these are not "acceptance criteria" in the context of an AI study measuring diagnostic performance.
In summary, the provided document does not contain the information requested in your bullet points because it is a regulatory submission for a data acquisition device, not a performance study for an AI algorithm.
{0}------------------------------------------------
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 26, 2016
Brainmaster Technologies, Inc. % Ms. Maria Griffin Official Correspondent MDI Consultants, Inc. 55 Northern Blvd. Suite 200 Great Neck, New York 11021
Re: K150498
Trade/Device Name: Discovery 24 Regulation Number: 21 CFR 882.1400 Regulation Name: Electroencephalograph Regulatory Class: Class II Product Code: GWO Dated: December 1, 2015 Received: December 4, 2015
Dear Ms. Griffin:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR
{1}------------------------------------------------
Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Michael J. Hoffmann -A
for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K150498
Device Name Discovery 24
Indications for Use (Describe)
Indicated for prescription use to acquire, record, transmit, and data for electroencephalograph studies of patients of all ages.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(K) SUMMARY
The assigned 510(k) number is:
-
- Submitter's Identification: Brainmaster Technologies, Inc. 195 Willis Street, Suite 3 Bedford. OH 44146
Contact Person: Tom Collura, President Tel: 440-232-6000 ext. 205
- Submitter's Identification: Brainmaster Technologies, Inc. 195 Willis Street, Suite 3 Bedford. OH 44146
Date Summary Prepared: January 25, 2016
2. Trade Name of the Device:
BrainMaster™ Discovery 24
-
- Common or Usual Name: full-montage standard electroencephalograph
Classification: 4.
Regulation: 21 CFR 882.1400 Product Code: GWQ
న. Predicate Device Information: The Vanguard System, K941551
6. Device Description:
The BrainMaster™ Discovery 24 are two-channel, four- channel, and 24-channel electrophysiological acquisition and biofeedback devices.
The 24-channel (Discovery 24) digital EEG devices use industry-accepted Windowsbased PC as the control and display console. The devices consist of the following:
- BrainMaster™ Discovery 24 Hardware Module 1.
-
- BrainMaster™ software - BrainMaster™ BrainAvatar Acquisition software
-
- Electrocap, which is sold separately.
The system also includes a full set of DIN-compliant touch-proof sockets, either on 4. the main housing, or in an accessory cable, that allows the use of compliant sensors for use of "free sensors" without a cap.
These products are designed for use with a standard IBM PC/AT compatible computers (Windows 7 and later) and associated peripheral equipment such as keyboard, mouse, and monitor(s). When assembled with a computer, the BrainMaster™ Discovery 24 system will acquire EEG and display and save it to disc.
{4}------------------------------------------------
7. Intended Use:
Indicated for prescription use to acquire, record, transmit, and display physiological and data for electroencephalograph (EEG) studies of patients of all ages.
8. Technological Comparison to Predicate Devices:
| PRODUCT | Cleveland ClinicVanguard System | BrainMasterDiscovery 24 |
|---|---|---|
| SCROLLED LIVE EEG | yes | yes |
| SYNCH VIDEO/EEG | yes | no |
| ADJUSTABLE VIEW | yes | yes |
| ADJUSTABLE VIEWDURATION | yes | yes |
| ONSCREEN MARKERS | yes | yes |
| DIGITAL FILTERING | yes | yes |
| MONTAGE EDITOR | yes | yes |
| REMOTE SCREEN VIEW | yes | yes |
| POWER | CPU (EISA) bus | Isolated Power via USBport |
| # OF EEG CHANNELS | 32-64 | 24 |
| A/D RESOLUTION | 12 bits | 24 bit |
| DIGITIZATION RATE | 200 Hz | 1024 Hz |
| SAMPLING RATE | 200 Hz | 256 Hz |
| IMPEDANCE CHECK | Yes | Yes |
| INDICATIONS FOR USE | Clinical EEG | Clinical EEG |
| SOFTWARE | EMach | BrainAvatar |
| PATIENT ISOLATION | optical | optical & magnetic |
| ISOLATION VOLTAGE | >2500V | >2500V |
| INTERFACE | EISA bus | USB |
| NOTCH FILTERING | 60/50 Hz | 60/50 Hz |
| COMMON MODEREJECTION RATIO | >110 dB | >120 dB |
| GAIN | 1000 | 16 |
| INPUT IMPEDANCE | >100MOhm | >1000GOhm |
| INPUT NOISE | 1.5uV at input | 1.5uV at input |
| SELF-CAL | yes | yes |
| FREQUENCY RANGE | 0.5 - 70 Hz | 0.5 - 70 Hz |
| Input Range | 1250 µV p-p | 100 mV p-p |
{5}------------------------------------------------
9. Discussion of Non-Clinical Tests Performed for Determination of Substantial Equivalence are as follows:
The following non-clinical tests were performed to support the determination of substantial equivalence;
IEC 60601-1-2 Ed. 3: 2007 Medical Electrical Equipment Part 1-2: General Requirements for Basic Safety and Essential Performance
IEC 60601-1-26 Ed. 3.0 B: 2012 Medical Electrical Equipment Part 2-26: Particular Requirements for the Basic Safety and Essential Performance of Electroencephalographs
Software Validation Testing per approved procedures
The devices passed all testing.
10. Discussion of Clinical Tests Performed: Not applicable.
11. Discussion of Substantial Equivalence
The BrainMaster system has the same intended use in the same environments as the predicate device. It has the same manner of use, being a computer-based digital EEG system with basic functions, and it has a similar requirement for training and expectations of user. The safety requirements and expectations are the same. The systems have comparable performance in terms of data sampling and accuracy, and speed and resolution of displays. They use identical patient connectors and methodology, being standard clinical EEG sensor placement.
12. Conclusions:
Based on the information provided in this submission we conclude that BrainMaster™ Discovery 24 is substantially equivalent to the predicate and are safe and effective for its intended use.
§ 882.1400 Electroencephalograph.
(a)
Identification. An electroencephalograph is a device used to measure and record the electrical activity of the patient's brain obtained by placing two or more electrodes on the head.(b)
Classification. Class II (performance standards).